Literature DB >> 20820914

Oncogramme, a new individualized tumor response testing method: application to colon cancer.

Elodie Loum1, Stephanie Giraud, Barbara Bessette, Serge Battu, Muriel Mathonnet, Christophe Lautrette.   

Abstract

Colon cancer is the second leading cause of cancer-related death in industrialized countries. Many anti-cancer researches are consequently performed and individualized tumor response testing (ITRT) methods are now used to individualize patient chemotherapeutic administrations. Then, a new ITRT method, Oncogramme, was developed for colon cancer. Colon tumor fragments from different patients were dissociated and seeded in a defined culture medium. Cell preparation process as well as culture medium allowed high cell viability and a good primary culture success rate. After treatment of isolated tumoral cells by chemotherapeutics alone or in combination, cytotoxicity was determined by cell death assay allowing the Oncogramme establishment, which was validated by statistical analysis. Indeed, significant results were obtained such as different profile for each patient's cells with various drugs, and variability between patient's cells in the response to each drug. Procedure described here to obtain the Oncogramme is a new, fast and technically reliable ITRT method applied to colon cancer. For an individualized cancer treatment use, this test should be further validated by a phase I clinical trial.

Entities:  

Year:  2010        PMID: 20820914      PMCID: PMC2993861          DOI: 10.1007/s10616-010-9298-5

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  22 in total

1.  Adjuvant therapy for colon cancer: the European experience.

Authors:  J Wils
Journal:  Tumori       Date:  2001 Jan-Feb       Impact factor: 2.098

2.  Use of in vitro tests in predictive cancer chemotherapy.

Authors:  A W Hamburger
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.

Authors:  C M Kurbacher; I A Cree; H W Bruckner; U Brenne; J A Kurbacher; K Müller; T Ackermann; T J Gilster; L M Wilhelm; H Engel; P K Mallmann; P E Andreotti
Journal:  Anticancer Drugs       Date:  1998-01       Impact factor: 2.248

5.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

Authors: 
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

8.  Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.

Authors:  Vera Loizzi; John K Chan; Kathryn Osann; Fabio Cappuccini; Philip J DiSaia; Michael L Berman
Journal:  Am J Obstet Gynecol       Date:  2003-11       Impact factor: 8.661

9.  Heterogeneity of malignant cells from a human colonic carcinoma.

Authors:  M G Brattain; W D Fine; F M Khaled; J Thompson; D E Brattain
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

Review 10.  A human three-dimensional cell line model allows the study of dynamic and reversible epithelial-mesenchymal and mesenchymal-epithelial transition that underpins colorectal carcinogenesis.

Authors:  Elizabeth Vincan; Thomas Brabletz; Maree C Faux; Robert G Ramsay
Journal:  Cells Tissues Organs       Date:  2007       Impact factor: 2.481

View more
  3 in total

1.  Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine.

Authors:  Maria Jeppesen; Grith Hagel; Anders Glenthoj; Ben Vainer; Per Ibsen; Henrik Harling; Ole Thastrup; Lars N Jørgensen; Jacob Thastrup
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

Review 2.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

3.  Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer.

Authors:  Christophe Bounaix Morand du Puch; Michelle Nouaille; Stéphanie Giraud; Anaïs Labrunie; Sandrine Luce; Pierre-Marie Preux; François Labrousse; Alain Gainant; Nicole Tubiana-Mathieu; Valérie Le Brun-Ly; Denis Valleix; Angélique Guillaudeau; Laura Mesturoux; Béma Coulibaly; Christophe Lautrette; Muriel Mathonnet
Journal:  J Transl Med       Date:  2016-01-12       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.